AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 145 filers reported holding AERIE PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $318,000 | +122.4% | 21,023 | +10.2% | 0.00% | – |
| Q2 2022 | $143,000 | -18.8% | 19,077 | -1.4% | 0.00% | – |
| Q1 2022 | $176,000 | +28.5% | 19,345 | -0.4% | 0.00% | – |
| Q4 2021 | $137,000 | -42.9% | 19,418 | -7.8% | 0.00% | – |
| Q3 2021 | $240,000 | -15.8% | 21,057 | +18.3% | 0.00% | – |
| Q2 2021 | $285,000 | +22.3% | 17,801 | +3.5% | 0.00% | – |
| Q4 2020 | $233,000 | +66.4% | 17,197 | +44.7% | 0.00% | – |
| Q3 2020 | $140,000 | -21.8% | 11,884 | -1.9% | 0.00% | – |
| Q2 2020 | $179,000 | 0.0% | 12,111 | -8.3% | 0.00% | – |
| Q1 2020 | $179,000 | -99.1% | 13,204 | -98.4% | 0.00% | -100.0% |
| Q4 2019 | $20,316,000 | +19.6% | 840,536 | -4.9% | 0.01% | +50.0% |
| Q3 2019 | $16,982,000 | -36.9% | 883,546 | -3.0% | 0.00% | -42.9% |
| Q2 2019 | $26,926,000 | -60.9% | 911,187 | -37.2% | 0.01% | -69.6% |
| Q1 2019 | $68,920,000 | +73.8% | 1,450,945 | +32.1% | 0.02% | +53.3% |
| Q4 2018 | $39,649,000 | -53.1% | 1,098,307 | -20.0% | 0.02% | -44.4% |
| Q3 2018 | $84,500,000 | -0.0% | 1,372,874 | +9.7% | 0.03% | -3.6% |
| Q2 2018 | $84,539,000 | +20.9% | 1,251,501 | -2.9% | 0.03% | +7.7% |
| Q1 2018 | $69,931,000 | +107.8% | 1,289,035 | +128.8% | 0.03% | +116.7% |
| Q4 2017 | $33,658,000 | +70.1% | 563,317 | +38.4% | 0.01% | +71.4% |
| Q3 2017 | $19,783,000 | +0.7% | 407,068 | +8.9% | 0.01% | +16.7% |
| Q2 2017 | $19,642,000 | +40.9% | 373,785 | +21.6% | 0.01% | +20.0% |
| Q1 2017 | $13,937,000 | +498.7% | 307,339 | +399.7% | 0.01% | +400.0% |
| Q4 2016 | $2,328,000 | +69.2% | 61,506 | -45.7% | 0.00% | 0.0% |
| Q1 2016 | $1,376,000 | -75.7% | 113,198 | -51.3% | 0.00% | -50.0% |
| Q4 2015 | $5,656,000 | +46.3% | 232,297 | +6.6% | 0.00% | 0.0% |
| Q3 2015 | $3,867,000 | +3262.6% | 217,977 | +3233.5% | 0.00% | – |
| Q2 2015 | $115,000 | – | 6,539 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 246,563 | $2,244,000 | 1.36% |
| LEVIN CAPITAL STRATEGIES, L.P. | 1,435,876 | $13,066,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,695,020 | $42,725,000 | 0.96% |
| DCF Advisers, LLC | 189,565 | $1,725,000 | 0.76% |
| DAFNA Capital Management LLC | 289,040 | $2,630,000 | 0.68% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,678,609 | $15,275,000 | 0.61% |
| Rhenman & Partners Asset Management AB | 589,200 | $5,362,000 | 0.53% |
| PFM Health Sciences, LP | 1,088,566 | $9,906,000 | 0.37% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 309,778 | $2,819,000 | 0.36% |
| Granahan Investment Management | 1,588,944 | $14,459,000 | 0.36% |